JP2018515605A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515605A5 JP2018515605A5 JP2018510322A JP2018510322A JP2018515605A5 JP 2018515605 A5 JP2018515605 A5 JP 2018515605A5 JP 2018510322 A JP2018510322 A JP 2018510322A JP 2018510322 A JP2018510322 A JP 2018510322A JP 2018515605 A5 JP2018515605 A5 JP 2018515605A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- composition
- subject
- ldl
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562158157P | 2015-05-07 | 2015-05-07 | |
| US62/158,157 | 2015-05-07 | ||
| PCT/US2016/031109 WO2016179456A1 (en) | 2015-05-07 | 2016-05-06 | Use of cd24 for lowering low-density lipoprotein cholesterol levels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515605A JP2018515605A (ja) | 2018-06-14 |
| JP2018515605A5 true JP2018515605A5 (https=) | 2019-04-11 |
| JP6751756B2 JP6751756B2 (ja) | 2020-09-09 |
Family
ID=57218627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510322A Expired - Fee Related JP6751756B2 (ja) | 2015-05-07 | 2016-05-06 | 低密度リポタンパク質コレステロールレベルを低下させるためのｃｄ２４の使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10369197B2 (https=) |
| EP (1) | EP3292144B1 (https=) |
| JP (1) | JP6751756B2 (https=) |
| KR (1) | KR20170141216A (https=) |
| CN (1) | CN107531772B (https=) |
| AU (1) | AU2016258084B2 (https=) |
| BR (1) | BR112017022394A2 (https=) |
| CA (1) | CA2982612A1 (https=) |
| EA (1) | EA038520B1 (https=) |
| ES (1) | ES2829235T3 (https=) |
| HK (1) | HK1249521A1 (https=) |
| HR (1) | HRP20201651T1 (https=) |
| HU (1) | HUE051866T2 (https=) |
| IL (1) | IL255086B (https=) |
| MX (1) | MX385941B (https=) |
| PT (1) | PT3292144T (https=) |
| WO (1) | WO2016179456A1 (https=) |
| ZA (1) | ZA201706846B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017022394A2 (pt) * | 2015-05-07 | 2018-07-17 | Oncoimmune Inc | uso de cd24 para diminuir níveis de colesterol das lipoproteínas de baixa densidade |
| WO2018165204A1 (en) * | 2017-03-07 | 2018-09-13 | Oncoimmune, Inc. | Methods of use of soluble cd24 for treating systemic lupus erythematosus |
| WO2019113123A1 (en) * | 2017-12-04 | 2019-06-13 | Precithera, Inc. | TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING |
| JP2021523929A (ja) * | 2018-03-05 | 2021-09-09 | オンコイミューン， インコーポレイテッド | 後天性免疫不全症候群（ｈｉｖ／ａｉｄｓ）の治療のための可溶性ｃｄ２４の使用方法 |
| WO2019236474A1 (en) * | 2018-06-04 | 2019-12-12 | Oncoimmune, Inc. | Methods of use of cd24 for the prevention and treatment of leukemia relapse |
| EP3870604B1 (en) | 2018-10-26 | 2022-11-23 | F. Hoffmann-La Roche AG | Multispecific antibody screening method using recombinase mediated cassette exchange |
| EP3921338A4 (en) * | 2019-02-06 | 2022-11-23 | Oncoimmune Inc. | TARGETED CD24-SIGLEC INTERACTIONS TO TREAT AND PREVENT NON-ALCOHOLIC STEATOHEPATITIS |
| US20220000974A1 (en) * | 2019-02-06 | 2022-01-06 | Oncolmmune, Inc. | Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes |
| WO2021160173A1 (en) * | 2020-02-10 | 2021-08-19 | Oncoimmune, Inc. | Methods of use of soluble cd24 for treating viral pneumonia |
| WO2021160170A1 (en) * | 2020-02-10 | 2021-08-19 | Oncoimmune, Inc. | Methods of use of soluble cd24 for treating sars-cov-2 infection |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544566B1 (en) * | 1999-04-23 | 2003-04-08 | Protein Technologies International, Inc. | Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol |
| EP1267909B1 (en) * | 2000-03-29 | 2010-07-28 | The Ohio State University Research Foundation | Methods of blocking tissue destruction by autoreactive t cells |
| CN1323544A (zh) * | 2000-05-13 | 2001-11-28 | 蛋白质技术国际公司 | 降低低密度脂蛋白胆固醇浓度的组合物和方法 |
| US20110002846A1 (en) * | 2007-12-21 | 2011-01-06 | Univeristy of Rochester | Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neural and glial tumors of the brain |
| US8163281B2 (en) * | 2009-03-04 | 2012-04-24 | The Regents Of The University Of Michigan | Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis |
| US8354520B2 (en) * | 2009-12-10 | 2013-01-15 | Kaohsiung Medical University | Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug |
| DK2563385T3 (da) * | 2010-04-28 | 2017-11-06 | Oncoimmune Inc | Fremgangsmåder til anvendelse af opløselig cd24 til behandling af reumatoid artritis |
| US20130231464A1 (en) * | 2010-04-28 | 2013-09-05 | Oncolmmune, Inc. | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |
| AU2012267489B2 (en) * | 2011-06-10 | 2017-03-16 | The Trustees Of The University Of Pennsylvania | System and method of cytomic vascular health profiling |
| BR112017022394A2 (pt) * | 2015-05-07 | 2018-07-17 | Oncoimmune Inc | uso de cd24 para diminuir níveis de colesterol das lipoproteínas de baixa densidade |
-
2016
- 2016-05-06 BR BR112017022394A patent/BR112017022394A2/pt not_active IP Right Cessation
- 2016-05-06 JP JP2018510322A patent/JP6751756B2/ja not_active Expired - Fee Related
- 2016-05-06 WO PCT/US2016/031109 patent/WO2016179456A1/en not_active Ceased
- 2016-05-06 EP EP16790128.9A patent/EP3292144B1/en active Active
- 2016-05-06 ES ES16790128T patent/ES2829235T3/es active Active
- 2016-05-06 HK HK18107984.3A patent/HK1249521A1/zh unknown
- 2016-05-06 PT PT167901289T patent/PT3292144T/pt unknown
- 2016-05-06 CN CN201680026449.2A patent/CN107531772B/zh not_active Expired - Fee Related
- 2016-05-06 US US15/572,330 patent/US10369197B2/en not_active Expired - Fee Related
- 2016-05-06 CA CA2982612A patent/CA2982612A1/en not_active Abandoned
- 2016-05-06 EA EA201792418A patent/EA038520B1/ru unknown
- 2016-05-06 MX MX2017014095A patent/MX385941B/es unknown
- 2016-05-06 HR HRP20201651TT patent/HRP20201651T1/hr unknown
- 2016-05-06 KR KR1020177032235A patent/KR20170141216A/ko not_active Ceased
- 2016-05-06 HU HUE16790128A patent/HUE051866T2/hu unknown
- 2016-05-06 AU AU2016258084A patent/AU2016258084B2/en not_active Ceased
-
2017
- 2017-10-10 ZA ZA2017/06846A patent/ZA201706846B/en unknown
- 2017-10-17 IL IL255086A patent/IL255086B/en unknown
-
2019
- 2019-06-17 US US16/443,498 patent/US11026995B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515605A5 (https=) | ||
| JP7166478B2 (ja) | ヒトヒアルロニダーゼｐｈ２０の変異体及び薬物を含む皮下投与用医薬組成物 | |
| Lei et al. | Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig | |
| Deng et al. | Nav1. 7 is essential for nociceptor action potentials in the mouse in a manner independent of endogenous opioids | |
| Markusic et al. | Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies | |
| Pipe et al. | Hemophilia A gene therapy: current and next-generation approaches | |
| Veritti et al. | Neovascular age-related macular degeneration | |
| Chowdary | Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab: P. Chowdary | |
| Schellekens | Factors influencing the immunogenicity of therapeutic proteins | |
| US7303748B2 (en) | Method of treating eye injury with local administration of a VEGF inhibitor | |
| Pasi et al. | Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: results from the B‐YOND extension study | |
| JP2013527168A5 (https=) | ||
| EA029215B1 (ru) | Стабильные водные составы адалимумаба | |
| RS59179B1 (sr) | Formulacije etanercepta stabilizovane jonima magnezijuma | |
| JPH10511557A (ja) | 血管内皮細胞増殖因子の変種、それらの使用およびそれらの生産法 | |
| CN102470156A (zh) | 选择性作用于αvβ3整合素并缀合人血清白蛋白(HSA)变体的多肽及其药学用途 | |
| Klinge et al. | Hemophilia A-from basic science to clinical practice | |
| CN107531772A (zh) | Cd24用于降低低密度脂蛋白胆固醇水平的用途 | |
| Hermans et al. | Recombinant factor VIII Fc for the treatment of haemophilia A | |
| Sheffield et al. | Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits | |
| Sun et al. | Gene delivery of activated factor VII using alternative adeno-associated virus serotype improves hemostasis in hemophiliac mice with FVIII inhibitors and adeno-associated virus neutralizing antibodies | |
| JP2016530284A (ja) | 疾患及び障害を治療するためにインターロイキン−１０を使用する方法 | |
| Miesbach et al. | Liver-related aspects of gene therapy for haemophilia: call to action for collaboration between haematologists and hepatologists | |
| Garger et al. | BAY 81‐8973, a full‐length recombinant factor VIII: manufacturing processes and product characteristics | |
| Valentino et al. | The biological efficacy profile of BAX 855, a PEG ylated recombinant factor VIII molecule |